Detalhe da pesquisa
1.
Long-term adaptation following influenza A virus host shifts results in increased within-host viral fitness due to higher replication rates, broader dissemination within the respiratory epithelium and reduced tissue damage.
PLoS Pathog
; 17(12): e1010174, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34919598
2.
Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.
Am J Pathol
; 184(4): 1050-1061, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24508126
3.
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Nat Chem Biol
; 4(6): 357-65, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18469809
4.
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
Mol Cancer Ther
; 6(12 Pt 1): 3158-68, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18089710
5.
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
PLoS One
; 8(3): e58424, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23520509
6.
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
Exp Hematol
; 38(4): 259-269.e2, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20167248
7.
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Mol Cancer Ther
; 9(3): 673-81, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20197397
8.
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
Anticancer Res
; 30(12): 4973-85, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21187478
9.
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
Mol Cancer Ther
; 9(8): 2243-54, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20682657
10.
Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate.
Mol Nutr Food Res
; 52(10): 1121-9, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18655005